Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation.

Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Settmacher U, Hommann M.

Transplant Res. 2012 Jun 1;1(1):7. doi: 10.1186/2047-1440-1-7.

2.

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Hommann M, Settmacher U.

Transplant Proc. 2012 Jun;44(5):1362-7. doi: 10.1016/j.transproceed.2012.01.133.

PMID:
22664016
3.

Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.

Shane E, Silverberg SJ, Donovan D, Papadopoulos A, Staron RB, Addesso V, Jorgesen B, McGregor C, Schulman L.

Am J Med. 1996 Sep;101(3):262-9.

PMID:
8873487
4.

Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.

Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Leidig-Bruckner G.

Osteoporos Int. 2003 Jan;14(1):82-9.

PMID:
12577189
5.

Regional bone mineral density after orthotopic liver transplantation.

Hussaini SH, Oldroyd B, Stewart SP, Roman F, Smith MA, Pollard S, Lodge P, O'Grady JG, Losowsky MS.

Eur J Gastroenterol Hepatol. 1999 Feb;11(2):157-63.

PMID:
10102226
6.

Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.

Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiébaud D, Burckhardt P.

Osteoporos Int. 2001;12(2):112-6.

PMID:
11303710
7.

Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.

Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W.

Liver Transpl. 2005 Aug;11(8):960-6.

8.

Pamidronate and osteoporosis prevention in liver transplant recipients.

Pennisi P, Trombetti A, Giostra E, Mentha G, Rizzoli R, Fiore CE.

Rheumatol Int. 2007 Jan;27(3):251-6. Epub 2006 Aug 31.

PMID:
16944154
9.
10.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
11.

Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.

Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R.

J Heart Lung Transplant. 2000 Aug;19(8):736-43.

PMID:
10967266
12.

Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.

Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E.

Scand J Gastroenterol. 2003 Mar;38(3):320-7.

PMID:
12737449
13.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD.

Bone. 2009 Mar;44(3):418-22. doi: 10.1016/j.bone.2008.09.011. Epub 2008 Oct 7.

PMID:
18950736
14.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

15.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
16.

Assessing bone status in patients awaiting liver transplantation.

Wibaux C, Legroux-Gerot I, Dharancy S, Boleslawski E, Declerck N, Canva V, Mathurin P, Pruvot FR, Cortet B.

Joint Bone Spine. 2011 Jul;78(4):387-91. doi: 10.1016/j.jbspin.2011.03.001. Epub 2011 May 11.

PMID:
21565541
17.

Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.

Guadalix S, Martínez-Díaz-Guerra G, Lora D, Vargas C, Gómez-Juaristi M, Cobaleda B, González EM, Hawkins F.

Transpl Int. 2011 Jul;24(7):657-65. doi: 10.1111/j.1432-2277.2011.01253.x. Epub 2011 Apr 5.

PMID:
21466595
18.

Influence of tacrolimus and short-duration prednisone on bone mineral density following liver transplantation.

Scolapio JS, DeArment J, Hurley DL, Romano M, Harnois D, Weigand SD.

JPEN J Parenter Enteral Nutr. 2003 Nov-Dec;27(6):427-32.

PMID:
14621125
19.

The effect of low-dose cholecalciferol and calcium treatment on posttransplant bone loss in renal transplant patients: a prospective study.

Sahin G, Yasar NS, Sirmagul B, Bal C, Yalcin AU.

Ren Fail. 2008;30(10):992-9. doi: 10.1080/08860220802406369.

PMID:
19016151
20.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk